Abstract
Although the clinical arsenal in treating cancer has been greatly extended in recent years with the application of new drugs and therapeutic modalities, the three basic approaches continue to be (in order of success) surgical resection, radiation, and chemotherapy. The latter treatment modality is primarily directed at metastatic cancer, which generally has a poor prognosis. A significant proportion of research investment is focused on improving the efficacy of chemotherapy, which is often the only hope in treating a cancer patient. Yet the challenges with chemotherapy are many. They include drug resistance by tumor cells, toxic effects on healthy tissue, inadequate targeting, and impaired transport to the tumor. Determination of proper drug dosage and scheduling, and optimal drug concentration can also be difficult. Finally, drug release kinetics at the tumor site is an important aspect of chemotherapy.
Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Similar content being viewed by others
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Alberts et al. Molecular Biology of the Cell. Taylor & Francis Group, New York, 2002.
R.P. Araujo and D.L.S. McElwain. A history of the study of solid tumour growth: the contribution of mathematical modeling. Bull. Math. Biol., June 2004. In press.
D. Barbolosi and A. Iliadis. Optimizing drug regimens in cancer chemotherapy: a simulation study using a PK-PD model. Comp. Biol. Med., 31:157–172, 2001.
L.A. Bauer. Applied Clinical Pharmacokinetics. Mc-Graw Hill, New York. pp. 26–45, 2001.
L.T. Baxter and R.K. Jain. Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: Comparison with experimental data. Brit. J. Canc., 73(4):447–456, 1996.
K.L. Black and N.S. Ningaraj. Modulation of brain tumor capillaries for enhanced drug delivery selectively to brain tumor. Cancer Control., 11(3):165–173, 2004.
G. Bonadonna, M. Zambetti, and P. Valagussa. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: ten year results. J. Am. Med. Assoc., 273:542–547, 1995.
I. Brigger, C. Dubernet, and P. Couvreur. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Del. Reviews., 54(5):631–651, 2002.
CCO Formulary, Liposomal Doxorubicin, October 2003.
M. Chaplain and A. Anderson. Mathematical modelling of tumour-induced angiogenesis: network growth and structure. Cancer Treat Res., 117:51–75, 2004.
M.L. Citron, D.A. Berry, C. Cirrincione, C. Hudis, E.P. Winer, W.J. Gradishar, N.E. Davidson, S. Martino, R. Livingston, J.N. Ingle, E.A. Perez, J. Carpenter, D. Hurd, J.F. Holland, B.L. Smith, C.I. Sartor, E.H. Leung, J. Abrams, R.L. Schilsky, H.B. Muss, and L. Norton. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/cancer and leukemia group B trial 9741. J. Clin. Oncol., 21(8):1431–1439, 2003.
P. Costa and J.M.S. Lobo. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci., 13:123–133, 2001.
V. Cristini, J. Lowengrub, and Q. Nie. Nonlinear simulation of tumor growth. J. Math. Biol., 46:191–224, 2003.
V. Cristini, H.B. Frieboes, R. Getemby, S. Corenta, M. Ferrari, and S. Sinek. Morphological instability and cancer inussion. Clin. Cancer Res., (in press) 2005.
Z. Cui, C.H. Hsu, and R.J. Mumper. Physical characterization and macrophage cell uptake of mannan-coated nanoparticles. Drug Dev. Ind. Pharm., 29(6):689–700, 2003.
M.S. Dordal, A.C. Ho, M. Jackson-Stone, Y.F. Fu, C.L. Goolsby, and J.N. Winter. Flowcytometric assessment of the cellular pharmacokinetics of fluorescent drugs. Cytometry, 20:307–314, 1995.
P. Elamanchili, M. Diwan, M. Cao, and J. Samuel. Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine, 22(19):2406–12, 2004.
R.E. Eliaz, S. Nir, C. Marty, Jr. F.C. Szoka. Determination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes. Canc. Res., 64:711–718, 2004.
N. Faisant, J. Siepmann, and J.P. Benoit. PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release. Eur. J. Pharm. Sci., 15(4):355–366, 2002.
S.S. Feng and S. Chien. Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem. Eng. Sci., 58:4087–4114, 2003.
X. Gao, Y. Cui, R.M. Levenson, L.W. Chung, and S. Nie. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol., 22(8):969–76, 2004.
B. Gompertz. On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies. Philos. Trans. R Soc. Lond., 115:513–583, 1825.
R. Gref, P. Couvreur, G. Barratt, and E. Mysiakine. Surface-engineered nanoparticles for multiple ligand coupling. Biomaterials, 24(24):4529–4537, 2003.
C.J. Gulledge and M.W. Dewhirst. Tumor oxygenation: a matter of supply and demand. Anticancer Res., 16:741–750, 1996.
H. Hashizume, P. Baluk, S. Morikawa, J.W. McLean, G. Thurston, S. Roberge, R.K. Jain, and D.M. McDonald. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol., 156(4):1363–1380, 2000.
T. Higuchi. Rate of release of medicaments from ointment bases containing drugs in suspension. J. Pharm. Sci., 50:874–875, 1961.
S.K. Hobbs, W.L. Monsky, F. Yuan, W.G. Roberts, L. Griffith, V.P. Torchilin, and R.K. Jain. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proceedings of the National Academy of Sciences of the United States of America. vol. 95, pp. 4607–4612, 1998.
M. Holz and A. Fahr. Compartment modeling. Adv. Drug Del. Rev., 48(2–3):249–264, 2001.
M. Hombreiro-Perez, J. Siepmann, C. Zinutti, A. Lamprecht, N. Ubrich, M. Hoffman, R. Bodmeier, and P. Maincent. Non-degradable microparticles containing a hydrophilic and/or a lipophilic drug: preparation, characterization and drug release modeling. J. Control. Rel., 88(3):413–428, 2003.
A. Ito, Y. Kuga, H. Honda, H. Kikkawa, A. Horiuchi, Y. Watanabe, and T. Kobayashi. Magnetite nanoparticleloaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia. Cancer Lett., 212(2):167–175, 2004.
T.L. Jackson and H.M. Byrne. A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy. Math. Biosci., 164:17–38, 2000.
R.K. Jain and L.E. Gerlowski. Extravascular transport in normal and tumor tissues. Crit. Rev. Oncol. Hematol., 5(2):115–170, 1986.
R.K. Jain. Determinants of tumor blood flow: a review. Canc. Res., 48:2641–2658, 1988.
R.K. Jain and L.T. Baxter. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Res., 48:7022–7032, 1988.
R.K. Jain. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. (Suppl.), 50:814s–819s, 1990.
R.K. Jain. Delivery of molecular medicine to solid tumors: Lessons from in vivo imaging of gene expression and function. J. Control. Rel., 74:7–25, 2001.
R.K. Jain. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nature Med., 7(9):987–989, 2001.
H. Kitano. Computational systems biology. Nature, 420:206–210, 2002.
N. Kohler, G.E. Fryxell, and M. Zhang. A bifunctional poly(ethylene glycol) silane immobilized on metallic oxide-based nanoparticles for conjugation with cell targeting agents. J. Am. Chem. Soc., 126(23):7206–7211, 2004.
K.Kosmidis, P. Argyrakis, and P. Macheras.Areappraisal of drug release laws using Monte Carlo simulations: the prevalence of the Weibull function. Pharm. Res., 20(7):988–995, 2003.
J. Kreuter. Nanoparticles. In J. Kreuter, (ed.), Colloidal Drug Delivery Systems, Marcel Dekker, Inc. New York, Basel, Hong Kong, 1994.
A.K. Laird. Dynamics of tumor growth. Br. J. Canc., 18:490–502, 1964.
R. Langer and N.A. Peppas. Chemical and physical structure of polymers as carriers for controlled release of bioactive agents: A review. Rev. Macromol. Chem. Phys., C23:61–126, 1983.
R. Langer. Drug delivery and targeting. Nature, 392:6679, 5–10, 1998.
R. Langer. Biomaterials in drug delivery and tissue engineering: One laboratory’s experience. Acc. Chem. Res., 33:94–101, 2000.
J. Lankelma. Tissue transport of anti-cancer drugs. Curr. Pharm. Des., 8:1987–1993, 2002.
K.W. Leong, B.C. Brott and R. Langer. Bioerodible polyanhydrides as drug-carrier matrices. I: Characterization, degradation and release characteristics. J. Biomed. Mat. Res., 19:941–955, 1985.
A. Mantovani. Biology of disease. Tumor-associated macrophages in neoplastic progression: a paradigm for the in vitro function of chemokines. Lab. Invest., 71:5–16, 1994.
U. Massing and S. Fuxius. Liposomal formulations of anticancer drugs: selectivity and effectiveness. Drug Resis. Updat., 3:171–177, 2000.
S.R. McDougall, A.R.A. Anderson, and M.A.J. Chaplain et al. Mathematical modelling of flow through vascular networks: Implications for tumour-induced angiogenesis and chemotherapy strategies. Bull. Math. Biol., 64(4):673–702, 2002.
K. Maruyama. In vivo targeting by liposomes. Biol. Pharm. Bull., 23(7):791–799, 2000.
L.D. Mayer and J.A. Shabbits. The role of liposomal drug delivery in molecular and pharmacological strategies to overcome multidrug resistance. Can. Metas. Rev., 20:87–93, 2001.
B. Narasimhan. Mathematical models describing polymer dissolution: Consequences for drug delivery. Adv. Drug Del. Rev., 48(2–3):195–210, 2001.
National Cancer Institute (NCI) website at http://press2.nci.nih.gov/sciencebehind/nanotech.
National Institute of Nanotechnology (NINT) of Canada at www.industrymailout.com/industry/do/news/view?id=9003&print=1.
P. Netti and R.K. Jain. Interstitial transport in solid tumors. In L. Preziosi (ed.), Cancer Modeling and Simulation, Chapman & Hall/CRC, Boca Raton, London, New York, Washington, pp. 62–65, 2003.
National Institutes of Health (NIH) website at http://press2.nci.nih.gov/sciencebehind/nanotech.
L. Norton. Implications of kinetic heterogeneity in clinical oncology. Semin. Oncol., 12:231–249, 1985.
L. Norton and R. Simon. The Norton-Simon hypothesis revisited. Cancer. Treat. Res., 70:163–169, 1986.
L. Norton. A Gompertzian model of human breast cancer growth. Cancer. Res., 48:7067–7071, 1988.
L. Norton. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist, 3(suppl):30–35, 2001.
L. Norton. Karnofsky Memorial Lecture. ASCO, 2004.
T.P. Padera, B.R. Stoll, J.B. Tooredman, D. Capen, E. di Tomaso, and R.K. Jain. Cancer cells compress intratumour vessels. Nature, 427:695, 2004.
R.S. Parker and F.J. Doyle III. Control-relevant modeling in drug delivery. Adv. Drug Del. Rev., 48(2–3):211–228, 2001.
N.A. Peppas. Analysis of Fickian and non-Fickian drug release from polymers. Pharm. Acta. Helv., 60:110–111, 1985.
P.J. Polverini. How the extracellular matrix and macrophages contribute to angiogenesis-dependent diseases. Eur. J. Cancer, 32A(14):2430–2438, 1996.
F. Quian, G.M. Saidel, D.M. Sutton, A. Exner, and J. Gao. Combined modeling and experimental approach for the development of dual-release polymer millirods. J. Control. Rel., 83:427–435, 2002.
P. Sapra and T.M. Allen. Ligand-targeted liposomal anticancer drugs. Prog. Lipid Res., 42:439–462, 2003.
M. Sarntinoranont, F. Rooney, and M. Ferrari. Interstitial stress and fluid pressure within a growing tumor. Ann. Biomed. Eng., 31:327–335, 2003.
J. Siepmann and A. Goepferich. Mathematical modeling of bioerodible, polymeric drug delivery systems. Adv. Drug Del. Rev., 48(2–3):229–247, 2001.
J. Siepmann, N. Faisant, and J.P. Benoit.Anewmathematical model quantifying drug release from bioerodible microparticles using Monte Carlo simulations. Pharm. Res. 19(12):1885–1893, 2002.
J. Siepmann and N.A. Peppas. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv. Drug Del. Rev., 48(2–3):139–157, 2003.
J. Siepmann, N. Faisant, J. Akiki, J. Richard, and J.P. Benoit. Effect of the size of biodegradable micro particles on drug release: experiment and theory. J. Control. Rel., 96(1):123–134, 2004.
S. Simoes, J.N. Moreira, C. Fonseca, N. Duezguenes, and M. Pedroso de Lima. On the formulation of pH-sensitive liposomes with long circulation times. Adv. Drug Del. Rev., 56:947–965, 2004.
J. Sinek, H.B. Frieboes, X. Zheng, and V. Cristini. Chemotherapy simulations demonstrate fundamental transport limitations involving nanoparticles. Biomed. Microdev., 6(4):297–309, 2004.
T. Sonoda, H. Kobayashi, T. Kaku, T. Hirakawa, and H. Nakano. Expression of angiogenesis factors in monolayer culture, multicellular spheroid and in vivo transplanted tumor by human ovarian cancer cell lines. Cancer Lett., 196:229–237, 2003.
M.Y. Su, A.A. Najafi, and O. Nalcioglu. Regional comparison of tumor vascularity and permeability parameters measured by albumin-Gd-DTPA and Gd-DTPA. Magn. Reson. Med., 34(3):402–411, 1995.
M.Y. Su, A. Muhler, X. Lao, and O. Nalcioglu. Tumor characterization with dynamic contrast-enhanced MRI using MR contrast agents of various molecular weights. Magn. Reson. Med., 39(2):259–69, 1998.
B.G. Sumpter, D.W. Noid, and M.D. Barnes. Recent developments in the formation, characterization, and simulation of micron and nano-scale droplets of amorphous polymer blends and semi-crystalline polymers. Polymer, 44(16):4389–4403, 2003.
Trends in NanoTechnology (TNT) 2001 at nanoword.net/library/weekly/ aa091201a.htm.
P. Veng-Pedersen. Noncompartmentally-based pharmacokinetic modeling. Adv. Drug Del. Rev., 48(2–3):265–300, 2001.
C.H. Wang, J. Li, and C.S. Teo et al. The delivery of BCNU to brain tumors. J. Control. Rel., 61(1–2):21–41, 1999.
W. Weibull. A statistical distribution of wide applicability. J. Appl. Mechan., 18:293–297, 1951.
C.P. Winsor. The Gompertz curve as a growth curve. Proc. Natl. Acad. Sci., 18:1–8, 1932.
F. Yuan, M. Dellian, D. Fukumura, M. Leunig, D.A. Berk, V.P. Torchilin, and R.K. Jain.Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res., 55(17):3752–3756, 1995.
H.S. Zaki, M.D. Jenkinson, D.G. Du Plessis, T. Smith, and N.G. Rainov. Vanishing contrast enhancement in malignant glioma after corticosteroid treatment. Acta Neurochir., 146:841–845, 2004.
M. Zhang, Z. Yan, L.L. Chow, and C.H. Wan. Simulation of drug release from biodegradable polymeric microspheres with bulk and surface erosions. J. Pharm. Sci., 92(10):2040–2056, 2003.
X. Zheng, S.M. Wise, and V. Cristini. Nonlinear simulation of tumor necrosis, neo-vascularization and tissue invasion via an adaptive finite-element/level-set method. Bull. Math. Bio., 67:211–259, 2005.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science + Business Media, LLC
About this chapter
Cite this chapter
Frieboes, H.B., Sinek, J.P., Nalcioglu, O., Fruehauf, J.P., Cristini, V. (2006). Nanotechnology in Cancer Drug Therapy: A Biocomputational Approach. In: Ferrari, M., Lee, A.P., Lee, L.J. (eds) BioMEMS and Biomedical Nanotechnology. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-25842-3_15
Download citation
DOI: https://doi.org/10.1007/978-0-387-25842-3_15
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-25563-7
Online ISBN: 978-0-387-25842-3
eBook Packages: EngineeringEngineering (R0)